Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration

Allergy and Asthma Proceedings

Volumn 25, Issue 1, 2004, Pages 69-75

  Vogelson, Cullen T ^a   Abelson, Mark B ^b,c   Pasquine, Terri ^a   Stephens, Donna M ^a   Gamache, Daniel A ^a   Gross, Robert D ^d   Robertson, Stella M ^a   Yanni, John M ^a  

^a ALCON RESEARCH LTD   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; OLOPATADINE;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GUINEA PIG; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; PROVOCATION TEST; PRURITUS; SIDE EFFECT;

ADMINISTRATION, TOPICAL; ADULT; AGED; ALLERGENS; ANIMALS; ANTI-ALLERGIC AGENTS; CAPILLARY PERMEABILITY; CIRCADIAN RHYTHM; CONJUNCTIVITIS, ALLERGIC; DIBENZOXEPINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUINEA PIGS; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1642290810     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Immunol 79:541-545, 1997.
2. Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drag for treating ocular allergic diseases. J Pharmacol Exp Ther 278:1252-1261, 1996.
3. Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits TNFα release from human conjunctival mast cells. Ann Allergy Asthma Immunol 84:1-5, 2000.
4. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective antiallergic/ antihistaminic agent. J Ocular Pharmacol Ther 12:389-400, 1996.
5. Sharif NA, Xu SX, and Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocular Pharmacol Ther 12:401-407, 1996.
6. Sasaki Y, Ishii H, Ikemura T, et al. The antihistaminic effect of KW-4679, a novel antiallergic drug. Clin Pharmacol Ther 5:1825-1835, 1995.
7. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 88:379-397, 2002.
8. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 117:643-647, 1999.
9. Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits antiimmunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol. 87:424-429, 2001.
10. Ikemura T, Manabe H, Sasaki Y, et al. KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Int Arch Allergy Immunol 110:57-63, 1996.
11. Miyake K, Ohmori K, Ishii A, et al. Inhibitory effect of olopatadine hydrochloride (KW-4679), a novel antiallergic drug, on peptide leukotriene release from human eosinophils. Allergol Int 50:113-116, 2001.
12. Fukuishi N, Matsuhisa M, Shimono T, et al. Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils. Jpn J Pharmacol 88:463-466, 2002.
13. Roy AK. Ocular tissue distribution of olopatadine following a single topical ocular dose of a 0.2% olopatadine ophthalmic solution to male New Zealand white rabbits. Alcon Internal Report 023:33:0502, 2002.
14. 1 receptor. Jap J Pharmacol 61:87, 1993.
15. Abelson MB, Chambers WA, and Smith LM. Conjunctival allergen challenge: A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 108:84-88, 1990.
16. Abelson MB, and Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 125:797-804, 1998.
17. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 81:211-218, 1998.
18. Butrus S, Greiner JV, Discepola M, et al. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 22:1462-1472, 2000.
19. Spangler DL, Bensch G, and Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 23:1272-1280, 2001.
20. Berdy GJ, Spangler DL, Bensch G, et al. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% opthalmic solution in the conjunctival antigen challenge model. Clin Ther 22:826-833, 2000.
21. Abelson MB, and Welch DL. An evaluation of onset and duration of action of Patanol® (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin® (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand 78:60-63, 2000.
22. Aguilar AJ. Comperative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand 78:57-60, 2000.
23. Crampton HJ. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. Clin Ther 24:1800-1808, 2002.
24. Netland PA, Leahy C, and Krenzer KL. Emedastine ophthalmic solution 0. 05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol 130:717-723, 2000.